WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317313
CAS#: 132-17-2
Description: Benztropine is a synthetic compound derived from the combination of atropine and diphenhydramine that acts centrally to antagonize M1 muscarinic acetylcholine receptors. Benztropine has been used in the management of Parkinson’s disease symptoms to address involuntary tremor and dystonia. It can also increase the availability of dopamine by inhibiting uptake through the dopamine transporter.
MedKoo Cat#: 317313
Name: Benztropine Mesylate
CAS#: 132-17-2
Chemical Formula: C22H27NO4S
Exact Mass:
Molecular Weight: 401.52
Elemental Analysis: C, 65.81; H, 6.78; N, 3.49; O, 15.94; S, 7.99
Synonym: Benztropine Mesylate; Cogentin; Cogentin mesylate; MLS000737056; Benztropine methanesulfonate; NSC42199; ST50997629; Benzotropine mesylate
IUPAC/Chemical Name: (1R,3r,5S)-3-(benzhydryloxy)-8-methyl-8-azabicyclo[3.2.1]octane methanesulfonate
InChi Key: CPFJLLXFNPCTDW-BWSPSPBFSA-N
InChi Code: InChI=1S/C21H25NO.CH4O3S/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17;1-5(2,3)4/h2-11,18-21H,12-15H2,1H3;1H3,(H,2,3,4)/t18-,19+,20+;
SMILES Code: CN1[C@@H]2C[C@@H](OC(C3=CC=CC=C3)C4=CC=CC=C4)C[C@H]1CC2.OS(C)(=O)=O
Appearance: White to light yellow crystalline powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 401.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bogunovic O, Viswanathan R. Thrombocytopenia possibly associated with
olanzapine and subsequently with benztropine mesylate. Psychosomatics. 2000
May-Jun;41(3):277-8. PubMed PMID: 10849461.
2: Jackson CW, Cunningham K. Compatibility of haloperidol lactate with
benztropine mesylate. Am J Hosp Pharm. 1994 Dec 1;51(23):2962-3. PubMed PMID:
7879808.
3: Voinov H, Elefante V, Mujica R. Sinus bradycardia related to the use of
benztropine mesylate. Am J Psychiatry. 1992 May;149(5):711. PubMed PMID: 1575268.
4: Rosenberg JM, Sideman M, Kampa IS, McGuire H, Kampa L. Effects of benztropine
mesylate on haloperidol-induced prolactin secretion and serum haloperidol levels
in rats. J Pharm Sci. 1984 Dec;73(12):1833-5. PubMed PMID: 6527272.
5: Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in
chronic schizophrenic patients. Br J Psychiatry. 1983 Dec;143:584-90. PubMed
PMID: 6362765.
6: Thaler JS. Effects of benztropine mesylate (Cogentin) on accommodation in
normal volunteers. Am J Optom Physiol Opt. 1982 Nov;59(11):918-9. PubMed PMID:
7180936.
7: Halbreich U, Sachar EJ, Nathan RS, Asnis GM, Halpern FS. The effect of
benztropine mesylate on the prolactin response to haloperidol. Psychopharmacology
(Berl). 1980;72(1):61-5. PubMed PMID: 6781007.
8: Rapp MS. Benztropine mesylate and social anxiety. Am J Psychiatry. 1979
Dec;136(12):1611. PubMed PMID: 507226.
9: Sovner R, Dimascio A. The effect of benztropine mesylate in the rabbit
syndrome and tardive dyskinesia. Am J Psychiatry. 1977 Nov;134(11):1301-2. PubMed
PMID: 910992.
10: Stenson RL, Donion PT, Meyer JE. Comparison of benztropine mesylate and
amantadine HCl in neuroleptic-induced extrapyramidal symptoms. Compr Psychiatry.
1976 Nov-Dec;17(6):763-8. PubMed PMID: 791573.
11: el-Yousef MK, Manier DH. Letter: The effect of benztropine mesylate on plasma
levels of butaperazine maleate. Am J Psychiatry. 1974 Apr;131(4):471-2. PubMed
PMID: 4149998.
12: Kelly JT, Zimmermann RL, Abuzzahab FS, Schiele BC. A double-blind study of
amantadine hydrochloride versus benztropine mesylate in drug-induced
parkinsonism. Pharmacology. 1974;12(2):65-73. PubMed PMID: 4610599.
13: Stricklin MC. Collaborative study of a colorimetric determination of
benztropine mesylate in tablets and injections. J Assoc Off Anal Chem. 1973
May;56(3):681-3. PubMed PMID: 4779907.
14: Mushet GR, Dreifuss FE. Paroxysmal dyskinesia. A case responsive to
benztropine mesylate. Arch Dis Child. 1967 Dec;42(226):654-6. PubMed PMID:
4965319; PubMed Central PMCID: PMC2019877.
15: Hanlon TE, Schoenrich C, Freinek W, Turek I, Kurland AA.
Perphenazine-benztropine mesylate treatment of newly admitted psychiatric
patients. Psychopharmacologia. 1966;9(4):328-39. PubMed PMID: 4874349.
